Abstract
Clarifying the pathology of dementias such as Alzheimer’s disease and designing their therapeutic targets are potentially important for facilitating the development of drugs against the dementia. The biologics for treatment of dementia such as peptides, antibodies, and neurotrophic factors need drug delivery systems （DDS） that can efficiently bring them to the brain from administration sites. This review summarizes the nose-to-brain drug delivery strategy using cell-penetrating peptides （CPPs） that we have recently established. Our works suggest that intranasal coadministration with CPPs can effectively enhance the transport of biologics such as peptide drugs and antibodies to the brain parenchyma. Furthermore, the drugs delivered to the brain via the enhanced nose-to-brain transport can have the therapeutic potential in the dementia mouse models. The transport mechanisms associated with the enhanced nose-to-brain delivery of biologics via intranasal coadministration with CPPs are also summarized in this review.
